Schedule 13G ownership disclosure
Soleno Therapeutics Inc
COMMON STOCK · CUSIP: 834203309
Event date: 2025-06-30
- Filing-level shares
- 3,461,510
- Percent of class
- 6.9%
- T. Rowe Price Associates, Inc.
Shares: 3,461,510 · Class: 6.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000080255-25-000591
- Form type
- SCHEDULE 13G/A
- Filer
- PRICE T ROWE ASSOCIATES INC /MD/
- CIK
- CIK 80255
- Filed
- Aug 14, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership